Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 8/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031820 | 0.81 | CCR2 (0.39) | SLC6A2SLC6A4CCR2KCNH2CYP2D6 | |
| SCHEMBL5029381 | 0.81 | SLC6A4 (0.38) | SLC6A2SLC6A4CCR2KCNH2CYP2D6 | |
| SCHEMBL5027115 | 0.71 | CCR2 (0.43) | CCR2KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL5027120 | 0.71 | CCR2 (0.43) | CCR2KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL5027117 | 0.71 | CCR2 (0.43) | CCR2KCNH2CYP2D6MEN1KMT2A | |
| SCHEMBL29696502 | 0.68 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC18A3MEN1KMT2A | |
| SCHEMBL28724595 | 0.68 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC18A3MEN1KMT2A | |
| SCHEMBL21227921 | 0.68 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC18A3MEN1KMT2A | |
| SCHEMBL28722408 | 0.68 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC18A3MEN1KMT2A | |
| SCHEMBL17802185 | 0.66 | SLC6A2 (0.45) | SLC6A2SLC6A4CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | SLC6A2 2558/4885SLC6A4 1592/4885CCR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.